Abstract
Receptor tyrosine kinase Ror1 is widely expressed during embryogenesis but it is absent within most mature tissues. However, expression of Ror1 has been reported in multiple human malignancies including breast cancer. High level expression of Ror1 in breast adenocarcinoma was associated with aggressive disease. Breast cancer radioimmunoscintigraphy targeting Ror1 expression is an attractive object in molecular imaging especially nuclear medicine research. In this study, we evaluated production, quality control and preclinical qualifications of a gallium-67 labeled anti-Ror1 antibody to see if it has potential to be used as a SPECT tracer for diagnosis and monitoring of Ror1 expressed tumors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
